Treatment with PDC lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab PDC line Pharma, a clinical stage biotech
Preliminary results with PDC lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumour response in Non-Small Cell Lung Cancer